EXEL News and Press, Exelixis Inc. From 04/05/23

Believes the Company Must Focus R&D Efforts and Spending, Communicate a Coherent Strategy and Return Excess Capital to Shareholders in Order to Reverse Exelixis’ Track Record of Underperformance Intends to Nominate Three Accomplished, Independent Director Candidates Who Will Br...

2023-04-04 23:05:56 ET Exelixis ( NASDAQ: EXEL ) will face a proxy battle with hedge fund Farallon Capital, who last Monday announced it nominated three individuals for the biotech firm. When Farallon announced it would nominate directors last week, it hadn't decided yet i...

2023-04-04 10:00:00 ET Some people think investing in stocks requires a substantial amount of start-up capital. But even small and regular investments can go a long way. That's especially so right now as some excellent companies look pretty cheap on a price basis. With $25, investors can ac...

2023-03-27 17:50:01 ET Farallon Capital Management, which has a 7.2% stake in Exelixis ( NASDAQ: EXEL ), said that it intends to nominate three individuals to the biotech's board. They are Tomas Heyman, David Johnson and Robert Oliver, Jr. In an SEC filing , Farall...

2023-03-20 19:11:35 ET Although share repurchase programs have their detractors, investors tend to like when their companies announce them. This was the dynamic behind biotech stock Exelixis ' (NASDAQ: EXEL) more than 4% rise in price on Monday; by contrast, the S&P 500 inde...

2023-03-20 17:33:07 ET Farallon Capital Management, which has a 7.2% stake in Exelixis ( NASDAQ: EXEL ), said the biotech is undervalued and "needs to refresh the Board." In an SEC filing, Farallon said it has told company management its concerns about its poor stock perfo...

2023-03-20 07:13:52 ET Exelixis ( NASDAQ: EXEL ) has authorized $550M share repurchase program of the company’s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on an ongoing assessm...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be...

2023-03-18 06:14:00 ET You've probably heard the old saying, "The bigger they are, the harder they fall." That might be true, but when it comes to investing, smaller stocks can fall pretty hard as well. The best of them, though, don't stay down indefinitely. Three Fool.com contributors ...

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. ...